Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• APOL1 gene variants are linked to increased kidney disease risk in African Americans.
• High APOL1 levels are hypothesized as a critical factor in disease development.
• Understanding APOL1's role is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate if reducing APOL1 levels can prevent kidney disease.
• To evaluate the therapeutic potential of antisense oligonucleotides (ASO) targeting APOL1.

Main Methods:

• Utilized a podocyte-specific transgenic mouse model (G2APOL1 mice).
• Administered APOL1-targeting antisense oligonucleotides (ASO) to reduce APOL1 levels.
• Assessed kidney function and pathology markers, including albuminuria and fibrosis.

Main Results:

• APOL1 ASO treatment efficiently reduced APOL1 transcript levels.
• APOL1 ASO1 demonstrated significant protection against kidney disease markers.
• Therapeutic effects were observed even in established disease models.
• A strong correlation between APOL1 transcript levels and disease severity was found.

Conclusions:

• Lowering APOL1 levels via ASO is a viable strategy for kidney disease.
• APOL1 ASO represents a potential therapeutic approach for APOL1-associated glomerular diseases.